Starpharma to advance with phase III studies for VivaGel
Wednesday, 11 January, 2012
Starpharma has kicked off the year with a tick from the US Food and Drug Administration for its study design for phase III trials of VivaGel under the FDA’s Special Protocol Assessment scheme.
The agreement with the FDA confirms that the study design, endpoints, statistical analyses and other aspects of the trial are acceptable for achieving regulatory approval.
The company intends to undertake two phase III trials of VivaGen for the treatment of bacterial vaginosis (BV) this year, with results anticipated before the year’s end.
Assuming positive results, the company intends to partner in order to progress to marketing stage.
“Following our recent financing, we are also implementing various initiatives in collaboration with our CRO to expedite the trial timelines as much as possible,” said Dr Jackie Fairley, Chief Executive Officer of Starpharma.
Starpharma’s (ASX:SPL) is steady at $1.20.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
